We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Gut Microbiome Metabolomic Profiles Are Diagnostic for Liver Diseases

By LabMedica International staff writers
Posted on 08 Jul 2020
Print article
Image: Illustration depicts a healthy liver (left) and a liver with cirrhosis (Photo courtesy of [U.S.] National Institute of Diabetes and Digestive and Kidney Diseases)
Image: Illustration depicts a healthy liver (left) and a liver with cirrhosis (Photo courtesy of [U.S.] National Institute of Diabetes and Digestive and Kidney Diseases)
Liver disease researchers have developed a noninvasive method to diagnose nonalcoholic fatty liver disease (NAFLD) and predict progression to cirrhosis by analyzing metabolomic profiles produced by the microorganisms living in the gut (the microbiome).

NAFLD is the most common liver disorder worldwide and leading cause of chronic liver disease. The disease affects approximately 25% of the world's population. It is particularly common in developed nations, such as the United States, and affected about 75 to 100 million Americans in 2017. Over 90% of obese, 60% of diabetic, and up to 20% normal-weight people develop NAFLD. Genetic factors are known to play a major role in determining the likelihood of developing NAFLD. Since there are no methods for early detection of the disease, researchers have been searching for early biomarkers that could be used for this purpose.

Dysregulation of the gut microbiome has been linked in prior studies to the progression of NAFLD to advanced fibrosis and cirrhosis. To determine the diagnostic capacity of this association, investigators at the University of California San Diego (USA) compared stool microbiomes across 163 well-characterized participants encompassing non-NAFLD controls, NAFLD-cirrhosis patients, and their first-degree relatives.

The investigators employed the random forest machine learning algorithm and differential abundance analysis to identify discrete metagenomic and metabolomic signatures that were similarly effective in detecting cirrhosis. Combining the metagenomic signature with age and serum albumin levels accurately distinguished cirrhosis in etiologically and genetically distinct cohorts from geographically separated regions. Through the additional inclusion of serum aspartate aminotransferase levels, which are increased in cirrhosis patients, the investigators were able to discriminate cirrhosis from earlier stages of fibrosis.

"This is one of the first studies to show such a robust external validation of a gut microbiome-based signature across ethnicities and geographically distinct cohorts. The findings represent the possibility of creating an accurate, stool microbiome-based, non-invasive test to identify patients at greatest risk for cirrhosis," said senior author Dr. Rohit Loomba, professor of medicine at the University of California, San Diego. "Such a diagnostic tool is urgently needed."

The gut metabolomic profile study was published in the June 30, 2020 online edition of the journal Cell Metabolism.

Related Links:
University of California San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.